|
|
Article: Enhance Merging With Ardent For Delta Receptor Compounds.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Two companies working on premature ejaculation products and other complementary programs decided to merge operations in an effort to reach the market in 2007.
New York-based Enhance Biotech Inc. signed a definitive agreement to join with Ardent Pharmaceuticals Inc., of Research Triangle Park, N.C., issuing an undisclosed amount of stock.
Focused on the discovery and development of delta receptor compounds, privately held Ardent has a pipeline of preclinical and clinical candidates in the areas of moderate to severe pain, urinary incontinence, premature ejaculation, depression and cardio protection. It has a library of about 1,000 ...